Agios Pharma (AGIO) Reports Q4 Loss of $1.08/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AGIO Hot Sheet
Join SI Premium – FREE
Agios Pharma (NASDAQ: AGIO) reported Q4 EPS of ($1.08), versus ($0.76) reported last year. Revenue for the quarter came in at $6.22 million, versus $14.64 million reported last year.
For earnings history and earnings-related data on Agios Pharma (AGIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Assumes Agios Pharma (AGIO) at Buy
- Stifel Positive on Rapport Therapeutics (RAPP): 'remains on track to share longer-term safety data from the ph2a in 4Q26'
- Studio City International Holdings Limited (MSC) Reports Q3 Loss of $0.02
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
